Precipio, Inc. Q3 FY2024 earnings call

• Crossed 10,000 cases for the year in 2024, up from ~8,000 in 2023, impacting real people's lives in battling cancer.
• Pathology division has exceeded breakeven for two consecutive quarters and is growing organically. Goal is ~$20 million run rate for pathology division to generate positive cash flow and support R&D.
• Products division saw 13% revenue increase from Q2, making steady progress towards breakeven with three key customers in onboarding. Focus on recurring revenue, customer retention, and higher margins.
• Cash burn reduced by 75% from Q3 2023 to Q3 2024, from ~$1 million to $226,000, showing progress towards breakeven.

Pathology division: Q3 revenues were $4.5 million, a robust 18% increase from Q2, exceeding the division breakeven point for the second consecutive quarter. It aims to reach approximately $20 million run rate. Products division: Q3 revenues were $680,000, a 13% increase from Q2, with progress towards breakeven as they have three key customers in onboarding stages.

• Management sees no need for capital raises with current quarterly performance and cash position.
• Plan to participate in investor conferences, build analyst coverage, and other investor-related activities in 2025 to increase visibility and provide more insight into company performance and future expectations.

• Risks and uncertainties that could cause actual results to differ from forward-looking statements include matters listed in Risk Factors of annual report on Form 10-K for the year ended December 30, 2022, and other subsequent SEC filings.

Q: [Questions submitted by shareholders] A: Ilan Danieli addressed the submitted questions during the call, discussing business performance, progress towards breakeven, and plans to increase shareholder value through improved visibility and investor activities